{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:13Z","timestamp":1792131013992,"version":"4.4.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00932","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T04:18:12Z","timestamp":1599020292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD"],"prefix":"10.3389","volume":"11","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Himori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juichi","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1212\/NXI.0000000000000640","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain."},{"key":"B8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/WNO.0000000000000700","article-title":"Acute management of optic neuritis: an evolving paradigm","volume":"38","author":"Horton","year":"2018","journal-title":"J Neuroophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/WNO.0000000000000102","article-title":"The treatment of neuromyelitis optica","volume":"34","author":"Kowarik","year":"2014","journal-title":"J Neuroophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler."},{"key":"B16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","article-title":"Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica","volume":"282","author":"Viswanathan","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr Treat Options Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","article-title":"Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D","volume":"21","author":"Mealy","year":"2019","journal-title":"Int J MS Care."},{"key":"B25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of neuromyelitis optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr Treat Options Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"577236","DOI":"10.1016\/j.jneuroim.2020.577236","article-title":"Risk factors of attacks in neuromyelitis optica spectrum disorders","volume":"343","author":"Akaishi","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2015.05.013","article-title":"Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis","volume":"355","author":"Mealy","year":"2015","journal-title":"J Neurol Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J Refract Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1620\/tjem.210.307","article-title":"Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica","volume":"210","author":"Takahashi","year":"2006","journal-title":"Tohoku J Exp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4103\/picr.PICR_123_17","article-title":"Common pitfalls in statistical analysis: Logistic regression","volume":"8","author":"Ranganathan","year":"2017","journal-title":"Perspect Clin Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/1352458515617248","article-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","volume":"22","author":"Yamasaki","year":"2016","journal-title":"Mult Scler."},{"key":"B42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"Optic neuritis treatment trial. One-year follow-up results","volume":"111","author":"Beck","year":"1993","journal-title":"Arch Ophthalmol."},{"key":"B43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1177\/1352458512470310","article-title":"Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica","volume":"19","author":"Rost\u00e1sy","year":"2013","journal-title":"Mult Scler."},{"key":"B46","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/01658107.2015.1134586","article-title":"Syphilitic optic neuropathy: re-emerging cases over a 2-year period","volume":"40","author":"Apinyawasisuk","year":"2016","journal-title":"Neuroophthalmology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/pgmj.2004.020875","article-title":"Neurosyphilis with optic neuritis: an update","volume":"82","author":"Smith","year":"2006","journal-title":"Postgrad Med J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2010.05.009","article-title":"Lyme optic neuritis","volume":"295","author":"Blanc","year":"2010","journal-title":"J Neurol Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/01658107.2018.1520905","article-title":"Clinical characteristics of anti-aquaporin 4 antibody positive optic neuritis in Japan","volume":"43","author":"Yamagami","year":"2019","journal-title":"Neuroophthalmology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler."},{"key":"B53","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3892\/etm.2018.6273","article-title":"Diagnostic implications of MOG\/AQP4 antibodies in recurrent optic neuritis","volume":"16","author":"Peng","year":"2018","journal-title":"Exp Ther Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2055217318791196","DOI":"10.1177\/2055217318791196","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B56","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"116671","DOI":"10.1016\/j.jns.2020.116671","article-title":"Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)","volume":"410","author":"Akaishi","year":"2020","journal-title":"J Neurol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2377-10-45","article-title":"Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis","volume":"10","author":"Nakajima","year":"2010","journal-title":"BMC Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T22:19:16Z","timestamp":1668550756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":58,"alternative-id":["10.3389\/fneur.2020.00932"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00932","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"article-number":"932"}}